GEN Exclusives

More »

GEN News Highlights

More »
Dec 2, 2010

Bruker to Provide MS-Based Microbial Identification Tool to Public Hospital Network of Paris

  • Bruker will be supplying Assistance Publique Hôpitaux de Paris (APHP) with the company’s IVD MALDI Biotyper. It will function as the exclusive MALDI-TOF mass spectrometry-based microbial identification tool.

    Three hospitals—Bichat, Cochin, and Lariboisière—have each already ordered an IVD MALDI Biotyper system. Bruker notes that two other APHP hospitals have been working with its MALDI-TOF mass spectrometers for several years. The APHP hospitals will use the IVD MALDI Biotyper for identification of micro-organisms such as Gram-negative bacteria, Gram-positive bacteria, and yeasts.

    “We want to use MALDI-TOF mass spectrometry identification in routine clinical microbiology applications to achieve the precision in bacterial identification that could otherwise only be obtained using time-consuming sequence based identification,” says Martin Rottman, associate professor of microbiology at University of Versailles and Hospital Raymond Poincaré. “Indeed the currently available biochemical methods fail to identify many micro-organisms involved in bone and joint infections.”

    The MALDI Biotyper solution enables identification, taxonomical classification, or dereplication of microorganisms like bacteria, yeasts, and fungi. Classification and identification of microorganisms is achieved using high-throughput MALDI-TOF mass spectrometry.

    Applications include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product processing and quality control, as well as marine microbiology.

    The workflow can also be applied on all linear-only Bruker MALDI-TOF mass spectrometers under IVD-CE, i.e., the microflow benchtop instrument as well as the floor-standing, high-throughput autoflex. The MALDI Biotyper method requires minimal sample preparation efforts and offers low cost per sample, Bruker states.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?